Multicenter Polish Study of the Use of Bromocriptine in Perinatal Cardiomyopathy. New BioMarkers in the Early Diagnosis of Peripartum CardioMyopathy. PolBrom-PPCM

Description of the study: Peripartum cardiomyopathy (PPCM) is a life-threatening condition with decreased left ventricular systolic function (LVEF) <45%, occurring at the end of pregnancy or in the first months after delivery in women without previous heart disease.
Accurate data on PPCM are lacking in Poland. Approximately 50% of patients recover, while heart failure persists or progresses in half. Late diagnoses, associated with the lack of validated, PPCM-specific biomarkers, worsen the prognosis.

The project aims to assess the therapeutic effect of the new, intensified treatment regimen with bromocriptine at a dose of 2 x 2.5 mg for 14 days, then 1 x 2.5 mg for min. 42 days with an additional extension of therapy in NYHA class> I patients, no improvement in LVEF in TTE (LVEF <35% or no increase in LVEF by 10%) compared to the 7-day administration of bromocriptine at the minimum dose of 1 x 2.5 mg necessary to inhibit lactation.